CClinicalTrials.gg
WithdrawnNCT05746117CHANGE-BPUpdated Feb 18, 2025

Continual Vs. Routine Home Blood Pressure Monitoring and Management in Diverse Community Practice: CHANGE-BP

An interventional study of Aktiia Device and Upper arm cuff in Hypertension, sponsored by Aktiia SA. Withdrawn at 1 site in United States. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-18.

Sponsored by Aktiia SA · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Study aborted by the sponsor
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Study summary

The purpose of the CHANGE-BP study is to examine the change in in-office measured Blood Pressure (BP) from baseline to end of study (6-months) between participants randomized to either 1) Continual Blood Pressure Monitoring (CBPM), which includes receiving Aktiia's novel cuffless BP Research System that has an accompanying Aktiia Patient Interface smartphone application, and care delivered through a centralized Aktiia Provider Interface that displays device data and is accessible by a health care professional or 2) Home Blood Pressure Monitoring (HBPM), which includes a standard oscillometric blood pressure cuff and the standard blood pressure management care from a participant's primary care physician.

Read the detailed description

This is a prospective, unblinded, open-label, randomized clinical trial that will study the use of the investigational Aktiia Bracelet and an accompanying Provider Interface in hypertension management. The Aktiia Bracelet is a non-invasive blood pressure monitor intended to track systolic and diastolic blood pressure and heart rate.

Participants will attend a baseline visit, which will include a survey and blood pressure and anthropometric measurements. Participants will then be randomized to either the CBPM group, which includes the Aktiia Bracelet and care through a centralized Aktiia Provider Interface, or the HBPM group, which includes a standard blood pressure cuff and standard hypertension care. Individuals in the CBPM group will wear the Aktiia Bracelet for 6 months. During this time, a study-affiliated clinical pharmacist will monitor the individual's blood pressure through the Provider Interface and will potentially titrate the participant's blood pressure medications accordingly. After 6-months, all participants will return for an end of study visit that will include a survey and blood pressure and anthropometric measurements. Participants in the CBPM group will complete an additional survey to give their opinion on the Aktiia product.

02

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
  • Medical Device
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

Browse Hypertension studies →

Lead sponsor

Aktiia SA is the lead sponsor of 13 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 21-80 years old
  • Owns a smartphone that is an Android or iOS with a data plan
  • Fluent in written and spoken English as the technology is currently only available in English
  • Average of 3 BP readings in last 18 months of >140/90 OR last in-office BP >140/90 in the last 6 months as documented in their Electronic Health Record
  • Is a patient with Providence Health
  • Willing to attend the 2 in-person study visits
  • Is not participating in another study that is designed to influence blood pressure
  • Willing to wear the Aktiia bracelet for 6 months
  • Willing to be randomized to either group
  • Had a BMP in the last 12 months or is willing to get one at the discretion of the clinical pharmacist as standard of care

Exclusion criteria

Exclusion Criteria:

  • Blood pressure at the baseline in-office visit is too low (SBP \<140 mmHg AND DBP \<90 mmHg) OR is too high (SBP > 190 mmHg OR DBP > 120 mmHg)
  • Tachycardia (heart rate at rest > 120bpm)
  • Atrial fibrillation, persistent or chronic
  • Cardiomyopathy with LVEF \<40% documented within the past year
  • Diabetes Mellitus
  • Under active treatment for hyperthyroidism
  • Myxedema coma
  • Subclavian stenosis
  • Pheochromocytoma
  • Raynaud's disease
  • Trembling and shivering
  • Known pregnancy
  • Breastfeeding
  • Arteriovenous fistula
  • Arm amputation
  • Exfoliative skin disease
  • Lymphedema
  • Known allergy to silicone
  • Terminal medical condition with a life expectancy less than 2 years
  • CKD 4-5 (eGFR ≤ 30 mL/min)
  • Upper arm circumference \< 22 cm or > 42 cm
  • Wrist circumference \< 14 cm or > 21 cm
  • Adults unable to consent or who need a legally authorized representative to consent
  • Currently incarcerated or detained in accordance with federal regulations regarding prisoners (e.g., 45 CFR 46 Subpart C)
  • Diagnosed whitecoat hypertension
  • On hospice or going on hospice in the next 6-months
  • Currently undergoing or will undergo active IV infusions for chemotherapy
  • Any condition which, at the discretion of the enrolling investigator, would preclude their ability to comply with study procedures
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Continuous Blood Pressure Monitoring (CBPM)

    Participants will wear the Aktiia Bracelet for 6-months and potentially receive blood pressure medication titrations during the 6-month period.

    Device: Aktiia Device

  • Active comparator
    Home Blood Pressure Monitoring (HBPM)

    Participants will receive an upper arm cuff and standard hypertension care from their primary care physician.

    Device: Upper arm cuff

Interventions

  • DeviceAktiia Device

    The Aktiia Bracelet is a CE-marked medical device that will be used in accordance with its instructions for use. The bracelet non-invasively measures optical signals at the wrist, which are used to determine blood pressure. The bracelet comes with a bluetooth enabled upper arm cuff that can be used to take on-demand blood pressure measurements. All measurements are transmitted to a dashboard that a clinical pharmacist monitors during the participant's enrollment in the study.

  • DeviceUpper arm cuff

    A standard upper arm oscillometric cuff that can be used to take blood pressure at home.

06

What researchers measure

Primary outcomes

  1. Change in blood pressure

    Determine if there is a statistically greater reduction in in-office measured blood pressure from baseline to 6-months in the CBPM arm when compared to the HBPM arm

    Time frame: 6-months

Secondary outcomes

  1. Participant perception

    Statistics on participants' perception of an optical BP monitoring modality as compared to an oscillometric cuff

    Time frame: 6-months

  2. Participant engagement

    Statistics on participants' engagement with the Aktiia Research System over the 6-month period

    Time frame: 6-months

  3. Participant compliance

    Statistics on participants' compliance, which is operationalized as the number of measurements made each day by the Aktiia Research System and the number of times the user syncs their Aktiia bracelet with the Patient Interface for the CBPM arm. Statistics on the number of upper arm cuff measurements reported to their PCP in the HBPM arm.

    Time frame: 6-months

  4. Participant sociodemographics

    Statistics on the sociodemographic breakdown of the sample

    Time frame: 6-months

07

Study locations

1 site
  • Providence Health & Services
    Portland, Oregon 97225, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05746117
Lead sponsor
Aktiia SA
Responsible party
Sponsor
First posted
Feb 27, 2023
Start date
Dec 15, 2024 (estimated)
Primary completion
May 31, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Feb 18, 2025

Study contacts

Aaron Shoenkerman, MD
principal investigator · Providence Health & Services

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion